VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis

被引：44

作者：

Beuselinck, Benoit ^{[1
,2
,3
]}

Karadimou, Alexandra ^{[3
]}

Lambrechts, Diether ^{[4
,5
]}

Claes, Bart ^{[4
,5
]}

Wolter, Pascal ^{[1
,2
]}

Couchy, Gabrielle ^{[3
]}

Berkers, Joost ^{[6
]}

van Poppel, Hendrik ^{[6
]}

Paridaens, Robert ^{[1
,2
]}

Schoffski, Patrick ^{[1
,2
]}

Mejean, Arnaud ^{[7
]}

Verkarre, Virginie ^{[8
]}

Lerut, Evelyne ^{[9
]}

Joly, Florence ^{[10
]}

Lebret, Thierry ^{[11
]}

Gravis, Gwenaelle ^{[12
]}

Deplanque, Gael ^{[13
]}

Descazeaud, Aurelien ^{[14
]}

Leclercq, Nathalie Rioux ^{[15
]}

Molinie, Vincent ^{[16
]}

Patard, Jean-Jacques ^{[17
]}

Teghom, Corine ^{[18
]}

Elaidi, Reza ^{[18
]}

Zucman-Rossi, Jessica ^{[3
,18
]}

Oudard, Stephane ^{[3
,18
]}

机构：

[1] Katholieke Univ Leuven, Leuven Canc Inst, Univ Hosp Leuven, Dept Gen Med Oncol, Louvain, Belgium

[2] Katholieke Univ Leuven, Leuven Canc Inst, Univ Hosp Leuven, Expt Oncol Lab, Louvain, Belgium

[3] Univ Paris 05, INSERM, Genom Fonct Tumeurs Solides U674, Paris, France

[4] Katholieke Univ Leuven, Dept Oncol, Lab Translat Genet, Louvain, Belgium

[5] VIB, Vesalius Res Ctr, Louvain, Belgium

[6] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Urol, Louvain, Belgium

[7] Univ Paris 05, Georges Pompidou European Hosp, Dept Urol, Paris, France

[8] Univ Paris 05, Hop Necker Enfants Malad, Dept Pathol, Paris, France

[9] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Pathol, Louvain, Belgium

[10] Ctr Francois Baclesse, Dept Med Oncol, F-14021 Caen, France

[11] Hop Foch, Dept Urol, Suresnes, France

[12] Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France

[13] Clin St Joseph, Dept Med Oncol, Paris, France

[14] Hop Dupuytren, Dept Urol, Limoges, France

[15] CHU Rennes, Dept Pathol, Rennes, France

[16] Clin St Joseph, Dept Pathol, Paris, France

[17] Hop Bicetre, Dept Urol, Le Kremlin Bicetre, France

[18] Univ Paris 05, Georges Pompidou European Hosp, Dept Med Oncol, Paris, France

来源：

ACTA ONCOLOGICA | 2014年 / 53卷 / 01期

关键词：

BEVACIZUMAB PLUS IRINOTECAN; TARGETED THERAPY; INTERFERON-ALPHA; PROGRESSION; PACLITAXEL; SURVIVAL; EFFICACY; TRIAL;

D O I：

10.3109/0284186X.2013.770600

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. There are no validated markers that predict outcome in metastatic renal cell cancer (mRCC) patients treated with sunitinib. Recently, single nucleotide polymorphism (SNP) rs9582036 in VEGFR1 has been proposed as a predictor of progression-free survival (PFS) and overall survival (OS) to bevacizumab in patients with pancreatic cancer and rs7993418 in VEGFR1 as predictor for PFS in mRCC-patients treated with bevacizumab. Here, we aim to study the impact of these SNPs in mRCC patients treated with sunitinib. Methods. We included patients with mRCC treated in 15 institutions in France and Belgium. Patients received sunitinib as first-line targeted therapy. We assessed response, time-to-tumor progression (TTP), OS, and clinical and biochemical parameters associated with outcome. We genotyped rs9582036 and rs7993418 as well as three other surrounding SNPs in VEGFR1: rs9554320, rs9554316 and rs9513070. Association between SNPs and treatment outcome were studied by univariate analysis and by multivariate Cox regression using relevant clinical factors associated with TTP and OS as covariates. Findings. Ninety-one patients were included. We found that mRCC patients with the CC-variant in rs9582036 in VEGFR1 have a poorer response rate (RR) (0% vs. 46%, p = 0.028), a poorer PFS (10 vs. 18 months, p = 0.033 on univariate and 0.06 on multivariate analysis) and a poorer OS (14 vs. 31 months, p = 0.019 on univariate and 0.008 on multivariate analysis) compared to patients with the AC- and AA-genotypes. mRCC patients with the AA-variant in rs9554320 in VEGFR1 have a poorer PFS (12 vs. 21 months, p = 0.0066 on univariate and 0.005 on multivariate analysis) and a poorer OS (22 vs. 34 months, p = 0.019 on univariate and 0.067 on multivariate analysis) compared to patients with the AC- and CC-genotypes. Interpretation. mRCC patients with the CC-genotype in VEGFR1 SNP rs9582036 have a poorer response rate, PFS and OS when treated with sunitinib. These findings are in agreement with the association of rs9582036 and outcome observed in bevacizumab treated pancreatic cancer patients. Prospective validation of this SNP is warranted.

引用

页码：103 / 112

页数：10

共 21 条

[11] Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Miller, Kathy
Wang, Molin
Gralow, Julie
Dickler, Maura
Cobleigh, Melody
Perez, Edith A.
Shenkier, Tamara
Cella, David
Davidson, Nancy E.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26) : 2666 - 2676
[12] Motzer R, 2004, CLIN CANCER RES, V10, p6202S
[13] Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Motzer, Robert J.
Hutson, Thomas E.
Tomczak, Piotr
Michaelson, M. Dror
Bukowski, Ronald M.
Rixe, Olivier
Oudard, Stephane
Negrier, Sylvie
Szczylik, Cezary
Kim, Sindy T.
Chen, Isan
Bycott, Paul W.
Baum, Charles M.
Figlin, Robert A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) : 115 - 124
[14] Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Motzer, Robert J.
Hutson, Thomas E.
Tomczak, Piotr
Michaelson, M. Dror
Bukowski, Ronald M.
Oudard, Stephane
Negrier, Sylvie
Szczylik, Cezary
Pili, Roberto
Bjarnason, Georg A.
Garcia-del-Muro, Xavier
Sosman, Jeffrey A.
Solska, Ewa
Wilding, George
Thompson, John A.
Kim, Sindy T.
Chen, Isan
Huang, Xin
Figlin, Robert A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : 3584 - 3590
[15] Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
Patil, S.
Figlin, R. A.
Hutson, T. E.
Michaelson, M. D.
Negrier, S.
Kim, S. T.
Huang, X.
Motzer, R. J.
[J]. ANNALS OF ONCOLOGY, 2011, 22 (02) : 295 - 300
[16] Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing
Reumers, Joke
De Rijk, Peter
Zhao, Hui
Liekens, Anthony
Smeets, Dominiek
Cleary, John
Van Loo, Peter
Van Den Bossche, Maarten
Catthoor, Kirsten
Sabbe, Bernard
Despierre, Evelyn
Vergote, Ignace
Hilbush, Brian
Lambrechts, Diether
Del-Favero, Jurgen
[J]. NATURE BIOTECHNOLOGY, 2012, 30 (01) : 61 - U103
[17] Resistance to targeted therapy in renal-cell carcinoma
Rini, Brian I.
Atkins, Michael B.
[J]. LANCET ONCOLOGY, 2009, 10 (10) : 992 - 1000
[18] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Sandler, Alan
Gray, Robert
Perry, Michael C.
Brahmer, Julie
Schiller, Joan H.
Dowlati, Afshin
Lilenbaum, Rogerio
Johnson, David H.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) : 2542 - 2550
[19] Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Van Cutsem, Eric
Vervenne, Walter L.
Bennouna, Jaafar
Humblet, Yves
Gill, Sharlene
Van Laethem, Jean-Luc
Verslype, Chris
Scheithauer, Werner
Cosaert, Aijing Shang Jan
Moore, Malcolm J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) : 2231 - 2237
[20] Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
van der Veldt, Astrid A. M.
Eechoute, Karel
Gelderblom, Hans
Gietema, Jourik
Guchelaar, Henk-Jan
van Erp, Nielka P.
van den Eertwegh, Alfons J. M.
Haanen, John B.
Mathijssen, Ron H. J.
Wessels, Judith A. M.
[J]. CLINICAL CANCER RESEARCH, 2011, 17 (03) : 620 - 629

← 1 2 3 →